2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
2760
Carcinoma, Non-Small-Cell Lung
2260
Prostatic Neoplasms
1425
Colorectal Neoplasms
1290
Neoplasms
1258
Multiple Myeloma
1084
Lung Neoplasms
1048
Neoplasm Metastasis
994
Leukemia, Myeloid, Acute
984
Lymphoma
900
Melanoma
862
Pancreatic Neoplasms
818
Ovarian Neoplasms
805
Carcinoma, Hepatocellular
782
Stomach Neoplasms
753
Recurrence
750
Leukemia
733
Lymphoma, Non-Hodgkin
684
Leukemia, Lymphocytic, Chronic, B-Cell
665
Lymphoma, Large B-Cell, Diffuse
616
Squamous Cell Carcinoma of Head and Neck
615
Precursor Cell Lymphoblastic Leukemia-Lymphoma
605
Head and Neck Neoplasms
596
Brain Neoplasms
592
Carcinoma, Renal Cell
586
Glioblastoma
572
Rectal Neoplasms
563
Myelodysplastic Syndromes
522
Sarcoma
521
Lymphoma, Follicular
516
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Advanced Unresectable or Metastatic Solid Malignancy
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts